Related Experiment Video
Updated: Dec 7, 2025

12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.0K
Five men with arresting and relapsing cerebral adrenoleukodystrophy.
Aaron M Carlson1, Irene C Huffnagel2, Aad Verrips3
1Department of Neurology, University of Colorado, Denver, CO, USA.
Journal of Neurology
|September 30, 2020
Summary
X-linked adrenoleukodystrophy (ALD) can present with a relapsing form where inflammatory lesions spontaneously arrest and then reactivate. This highlights the need for ongoing monitoring in affected individuals.
Area of Science:
- Neurology
- Genetics
- Peroxisomal Disorders
Background:
- X-linked adrenoleukodystrophy (ALD) is a common genetic peroxisomal disorder affecting approximately 1:15,000 males.
- Two-thirds of males with ALD develop the cerebral phenotype (cALD), characterized by progressive inflammatory demyelinating lesions.
- Early hematopoietic stem-cell transplantation can halt cALD, but effectiveness diminishes with disease progression.
Purpose of the Study:
- To describe a previously undocumented variant of cerebral adrenoleukodystrophy (cALD) characterized by lesion arrest and subsequent relapse.
- To document the clinical and radiographic features of this novel arresting-relapsing cALD phenotype.
Main Methods:
- Review and summarization of clinical and radiographic data from cALD patients exhibiting episodic deteriorations.
- Longitudinal follow-up of patients with spontaneously arrested cALD lesions.
Main Results:
- Five unrelated men with cALD exhibited spontaneously arrested lesions that later showed renewed clinical and radiographic progression.
- In three of five patients, disease progression occurred when they were too debilitated for transplantation.
- One patient experienced lesion reactivation followed by another spontaneous arrest.
Conclusions:
- The findings underscore the importance of continuous clinical and radiographic surveillance in adult males with ALD.
- Vigilance is crucial for detecting new or reactivated cALD lesions to enable timely treatment evaluation.
- This study identifies a novel arresting-relapsing variant of cALD, necessitating adapted monitoring strategies.
Related Concept Videos
Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
Lysosomal Hydrolases
4.3K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.3K
Alzheimer's Disease: Treatment
634
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
634
Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K

